Swiss contract drug manufacturer Lonza said on Wednesday it would buy one of the world's largest manufacturing sites for biologic drugs in California from drugmaker Roche for $1.2 billion.

Narrow-moat Lonza provided a third-quarter qualitative update, and the company is tracking our 2024 expectations. We forecast flat sales growth in 2024, which reflects the impact of Moderna's ...

Lonza expands biologics manufacturing capacity with acquisition of Genentech facility in Vacaville, CA. $1.2 billion deal includes employee retention and facility upgrades. Transaction expected to ...

Lonza has acquired Genentech’s large-scale biologics manufacturing site in Vacaville, ... Lonza will manufacture existing products for Roche at a committed volume of 30% of capacity in 2025.

Lonza plans to invest approximately CHF 500 million to further upgrade the facility and add capabilities to meet demand for the next generation of mammalian biologics therapies. The products ...

Thursday, KeyBanc Capital Markets increased its price target for Lonza Group (LONN:SW) (OTC: LZAGY) shares to CHF 635 from CHF 610, while keeping an Overweight rating on the stock. The adjustment ...

Swiss contract drug manufacturer Lonza (OTCPK:LZAGF) (OTCPK:LZAGY) has agreed to acquire a large-scale biologics manufacturing site in California from Roche (OTCQX:RHHBY) (OTCQX:RHHBF) for $1.2B ...

He reported that Biologics' end-market capacity remains constrained, and acquiring more capacity won't lead to lower premium-priced products. In detail, Lonza will continue to manufacture Roche ...

The state’s largest pharma manufacturer – Lonza Biologics in Portsmouth – is in the process of getting larger still. Lonza, at the forefront of vaccination efforts to combat the Covid epidemic, is ...

(Reuters) -Swiss contract drug manufacturer Lonza said on Wednesday it would buy one of the world's largest manufacturing sites for biologic drugs in California from drugmaker Roche for $1.2 billion.

Lonza Group AG / Key word(s): Acquisition Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche 01.10.2024 / 16:45 CET/CEST The Vacaville site is one of the ...

Lonza, announced it has completed its acquisition of the Genentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche for USD 1.2 billion. The Vacaville facility ...